NTLA · Intellia Therapeutics, Inc.

A social post claims California is about to pass a bill banning “aesthetic” gene editing in pets and that the bill cites the author’s company; it frames this as regulation of technology (methods) rather than outcomes. No bill number, timing, or details are provided, so tradability is limited without verification.

The source is a one-line conceptual statement about aging as a drift from optimal gene expression. It provides no company, product, catalyst, timing, or investable details, so it is not directly actionable for trading without additional context (e.g., specific targets, modalities, clinical readouts, or firms).

This excerpt of NTLA’s 10‑Q (quarter ended 2026‑03‑31) contains only the SEC cover page/filing status and listing information, with no financial statements, guidance, program updates, risks, cash runway, or material events. It is therefore not actionable for trading on fundamentals.

ARK’s Big Ideas 2026 (Multiomics) segment outlines the investment case for “multiomics” (integrating genomics, transcriptomics, proteomics, etc.) as biology moves from single-layer measurement to multi-layer data + computation. The talk highlights downstream implications across (1) data generation (sequencing/single-cell/proteomics platforms), (2) diagnostics (earlier, cheaper, more precise testing), (3) drug development (better target ID/stratification), and (4) therapeutics (more precise, pote